Kymera Therapeutics shares surged 21.11% to $120.96 in Thursday morning trading after the clinical-stage biopharmaceutical company announced it completed enrollment in a key mid-stage eczema trial nearly six months ahead of schedule, allowing it to move up its closely watched data readout.

The Catalyst Behind the Surge

Kymera Therapeutics added roughly 10% in premarket trading Thursday after announcing an expedited timeline to share topline data from a mid-stage trial for KT-621, its experimental therapy for atopic dermatitis, commonly known as eczema. The global Phase 2b trial, named BROADEN2, evaluates the drug in patients with the condition.

Kymera Therapeutics shares rose 8.8% in premarket trading Thursday after the company completed enrollment in its Phase 2b atopic dermatitis trial nearly six months ahead of schedule. The company announced it finished enrollment in the BROADEN2 Phase 2b trial of KT-621, its oral STAT6 degrader, for moderate to severe atopic dermatitis. The accelerated enrollment allows Kymera to move up its topline data readout by six months to year-end 2026, earlier than previous guidance of mid-2027.

The BROADEN2 trial is a global, randomized, double-blind, placebo-controlled study evaluating three doses of KT-621 in approximately 200 adult and adolescent patients aged 12 to 75 with moderate to severe atopic dermatitis over 16 weeks. The primary endpoint measures the percent change from baseline in Eczema Area and Severity Index score at Week 16.

A Company Built Around Protein Degradation

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade........

© International Business Times